FIGURE

Fig. 1

ID

ZDB-FIG-220719-61

Publication

B�r et al., 2022 - Chimeric HDAC and the cytoskeleton inhibitor broxbam as a novel therapeutic strategy for liver cancer

Other Figures

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12
Fig. 13

All Figure Page

Back to All Figure Page

Fig. 1

Molecular structures of Broxbam and vorinostat. Structures of the vascular disrupting agents combretastatin A-4 (CA-4), the histone deacetylase-inhibitor vorinostat (red) and the oxazole-bridged hybrid compound broxbam.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Int. J. Oncol.